- Companies
- NantOmics
NantOmics Valuation, Funding & Investors
NantOmics is valued at $1.7B as of June 2015.
Last NantOmics valuation
$1.7B
Series A · Jun 2015
Last NantOmics funding round
$251M
Series A · Jun 2015
Cumulative funding NantOmics raised
$251M
across 1 funding round
Key investors in NantOmics
About NantOmics
NantOmics is a Culver City-headquartered molecular diagnostics company that develops cloud-based molecular profiling tools, including the GPS Cancer test and OncoPlexDx Targeted Proteomic panel, to guide personalized cancer treatments for patients and oncologists. As a subsidiary of NantWorks, it delivers point-of-care insights into cancer biology through quantitative protein biomarkers and genomic profiles. NantOmics supports treatment strategies in clinical settings across the United States, with headquarters in California and integration into broader precision medicine platforms.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Services, Product sales
Valuation
$1.7B (Jun 2015)
NantOmics Valuation
NantOmics is currently valued at $1.7B, based on its Series A in June 2015.
The $251M round was led by NantHealth.
NantOmics valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jun 2015 | Series A | $1.7B |
NantOmics Funding History
NantOmics has raised a total of $251M across 1 funding round.
NantOmics funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jun 2015 | Series A | NantHealth (lead) | $251M | $1.7B | NantOmics, a molecular diagnostics arm of NantWorks founded by Patrick Soon-Shiong, specializes in precision medicine with a cloud-based infrastructure for processing thousands of genomes daily, computing genomic variances in near real-time, and correlating proteomic pathway analysis from tumor samples. It operates the nation’s only CAP- and CLIA-certified whole genome and quantitative proteomics laboratory, providing genomic insights like the GPS Cancer platform licensed to sister company NantHealth. In September 2015, it completed the acquisition of OncoPlex Diagnostics, a proteomics lab funded by Soon-Shiong subsidiaries since 2008. In June 2015, NantHealth invested a substantial portion of its capital in NantOmics, acquiring approximately 14.2% to 14.3% of the issued and outstanding membership interests for $52.5 million, as detailed in SEC filings and NantHealth's S-1 for its IPO. This investment gave NantHealth access to NantOmics' advanced lab capabilities to enhance its CLINICS platform, which integrates NantOS apps, GPS Cancer, and other tools. NantWorks operates as an ecosystem of interrelated entities, with Soon-Shiong orchestrating funding and M&A among subsidiaries like NantHealth, NantCell, and NantOmics. NantHealth's 2015 net revenue was $58.3 million with a $72 million net loss. Later, in 2016, NantHealth recorded a $29.8 million impairment on its NantOmics investment due to delayed GPS test sales growth and a $41 million loss from the equity method investment. The investment supported NantOmics' role in NantHealth's precision care platforms serving over 2,000 hospitals, 70 health plans, and 100 million patients. |
Who has invested in NantOmics?
1 investor has backed NantOmics across its funding rounds, including NantHealth.
Lead investors include NantHealth.
NantOmics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
This data is available for Pro users. Sign up to see all 1 NantOmics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by NantOmics
NantOmics has acquired 2 companies to date.
Last acquisition by NantOmics was on April 13th 2017. NantOmics acquired Genos for undisclosed valuation.
Latest Acquisitions by NantOmics
| Description | Genos is a consumer genomics company based in Mountain View, California, empowering individuals with personal control over their DNA data. The firm offers whole-genome sequencing kits that allow users to store and share genomic information selectively with researchers and partners. Genos facilitates community-driven research projects in rare diseases and traits through its data marketplace, connecting sequenced genomes to academic studies worldwide. | OncoPlexDx is a CLIA-certified laboratory in Rockville, Maryland, providing multiplex proteomics assays for cancer therapy selection. Analyzing 143 proteins via immunoassay, it guides precision treatment in breast, lung, and colorectal cancers, correlating with outcomes in 1,000 patient cohorts to avoid ineffective therapies. |
| HQ Country | ||
| HQ City | San Francisco, CA | Washington, DC |
| Deal Date | 13 Apr 2017 | 10 Sep 2015 |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all NantOmics acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by NantOmics
NantOmics has invested in 1 company to date.
Latest investment by NantOmics was on September 1st 2015. NantOmics invested in Translational Research Management in their $800K Seed round.
Latest Investments by NantOmics
| Description | Translational Research Management is a Plymouth Meeting-headquartered organization building a network of over 100 community oncology practices across the United States. TRM facilitates access to more than 500 active clinical trials for cancer patients, partnering with pharma sponsors like Merck and Bristol Myers Squibb. The firm manages regulatory compliance and site activation nationwide. |
| HQ Country | |
| HQ City | Los Angeles, CA |
| Deal Date | 1 Sep 2015 |
| Round | Seed |
| Raised | $800K |
| Investors | - |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all NantOmics investments and their VC round multiples. Start Free Trial | |
NantOmics Competitors
NantOmics competitors include listed companies like Revvity, Dian Diagnostics Group and Vimian Group, and private ones like Iterative Health, Unite Us and NantHealth.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $1.3B | - | ||
| Publicly listed | $2.9B | $735M | $16B | 6.6x | ||
| Publicly listed | $1.5B | $127M | $1.7B | 1.4x | ||
| Publicly listed | $489M | $119M | $1.9B | 4.0x | ||
| Private | - | - | $1.6B | - | ||
| Private | $58M | - | $2B | - |
NantOmics Public Comps
NantOmics is still privately-owned, but its public comps include Dian Diagnostics Group, Vimian Group, JMDC, Indegene, Diagnostyka, Nutex Health, Ramsay Santé, Butterfly Network, Certara and Sinocare.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.5B | $127M | 1.4x | 1.4x | 16.4x | 12.2x | |||
| $489M | $119M | 4.4x | 4.0x | 17.9x | 14.4x | |||
| $324M | $88M | 5.0x | 4.6x | 18.4x | 17.9x | |||
| $366M | $68M | 3.7x | 3.3x | 19.9x | 18.2x | |||
| $637M | $154M | 2.8x | 2.5x | 11.6x | 10.5x | |||
| $875M | $288M | 2.0x | 2.0x | 6.0x | 6.4x | |||
| $6.2B | $720M | 0.9x | - | 8.0x | - | |||
| $98M | ($73M) | 20.6x | 17.6x | (27.5x) | (93.5x) | |||
This data is available for Pro users. Sign up to see all NantOmics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about NantOmics
| When was NantOmics founded? | NantOmics was founded in 2012. |
| Where is NantOmics headquartered? | NantOmics is headquartered in Los Angeles, CA, United States. |
| Is NantOmics publicly listed? | No, NantOmics is a private, VC-backed company. |
| What is NantOmics' valuation? | NantOmics was last valued at $1.7B in its Series A in June 2015. |
| How much funding has NantOmics raised? | NantOmics has raised $251M across 1 funding round. |
| What was NantOmics' last funding round? | NantOmics' last funding round was a $251M Series A in June 2015, led by NantHealth. |
| Who are NantOmics' investors? | NantOmics' investors include NantHealth. |
| Which companies are comparable to NantOmics? | Companies comparable to NantOmics include Iterative Health, Revvity, Dian Diagnostics Group, Vimian Group, Unite Us and NantHealth. |
| How many companies has NantOmics acquired? | NantOmics has acquired 2 companies, including Genos and OncoPlexDx. |
| How many companies has NantOmics invested in? | NantOmics has invested in 1 company, including Translational Research Management. |
| What was NantOmics' last investment? | In September 2015, NantOmics invested in Translational Research Management's $800K seed round. |
See companies similar to NantOmics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




